Luxana Biotech Co., Ltd. Expands Strategic XNA Partnership with BioSpring

Key Points:

· Luxana Biotech Co., Ltd. and BioSpring have expanded their existing collaboration, enabling BioSpring to manufacture next-generation custom oligonucleotides incorporating Luxana Biotech’s GuNA™ amidite, in addition to AmNA™, scpBNA™, and 5′-CP™.

· The addition of GuNA™ further broadens the range of Luxana Biotech’s proprietary Xeno Nucleic Acid (XNA) chemistry available through BioSpring’s oligonucleotide manufacturing services.

· GuNA™-modified oligonucleotides may enhance nuclease resistance, improve target binding, and reduce immunotoxicity and neurotoxicity, offering potential applications in developing more effective and safer nucleic acid therapeutics for neurodegenerative diseases.

Luxana Biotech Co., Ltd. (President and CEO: Hidetoshi Sato, headquarters: Suita City, Osaka Prefecture, hereinafter “Luxana Biotech”) is advancing research and development of oligonucleotide therapeutics based on its proprietary Xeno Nucleic Acid (XNA) technology. The company today announced the expansion of its partnership with BioSpring GmbH (hereinafter “BioSpring”), a provider of high-quality therapeutic oligonucleotide manufacturing, regarding XNA-modified oligonucleotide manufacturing services.

With this expanded collaboration, BioSpring will be able to offer broader manufacturing support to biotechnology and pharmaceutical companies developing next-generation oligonucleotide therapeutics using Luxana Biotech’s proprietary XNA technology. GuNA™ is one of the artificial nucleic acid technologies comprising Luxana Biotech’s XNA technology platform, featuring beneficial properties for antisense oligonucleotide design, including enhanced nuclease resistance, improved base-specific hybridization, introduction of positive charges into the oligonucleotide backbone, and reduced immunotoxicity and neurotoxicity.

Furthermore, by adding GuNA™ to BioSpring’s XNA-modified oligonucleotide manufacturing services, both companies can now provide biotechnology and pharmaceutical companies with broader access to advanced XNA chemistry. This partnership reflects the shared commitment of both companies to support customers by advancing innovation in modified oligonucleotide design and providing reliable manufacturing support.

Hidetoshi Sato, President and CEO of Luxana Biotech, stated:

"We are very pleased to include GuNA™ in our collaboration with BioSpring. GuNA™ is a key artificial nucleic acid technology within our XNA technology platform. With this expanded partnership, more biotechnology and pharmaceutical companies will now be able to explore the potential of GuNA™ through BioSpring’s reliable oligonucleotide manufacturing services. In particular, we expect the combination of GuNA™ and 5′-CP™ to contribute to improved efficacy and safety in nucleic acid therapeutics targeting central nervous system disorders."

Dr. Hüseyin Aygün, Chief Scientific Officer (CSO) of BioSpring, stated:

"This expanded partnership marks an important next step in our collaboration with Luxana Biotech. With the addition of GuNA™, we can now offer our customers a wider range of advanced XNA chemistry for the design and manufacturing of modified oligonucleotides. This further strengthens BioSpring’s role as a partner in the development of innovative oligonucleotide therapeutics."

For inquiries regarding oligonucleotide manufacturing using Luxana Biotech’s XNA amidites, please contact BioSpring.

Contact: BioSpring GmbH

https://www.biospring.net/contact

About Luxana Biotech Co., Ltd.

Luxana Biotech Co., Ltd. is a biotechnology company leveraging artificial nucleic acids developed from the research of Professor Satoshi Kobika at the Graduate School of Pharmaceutical Sciences, Osaka University. Through its proprietary drug discovery platform “LuxiAP™,” the company advances the research and development of safer and more effective oligonucleotide therapeutics.

Since its establishment in 2017, Luxana Biotech has aimed to realize new treatments for intractable diseases and has promoted the development of innovative oligonucleotide therapeutics through collaborations with multiple pharmaceutical companies.

For more information, please visit our website.

https://luxnabiotech.co.jp/

LinkedIn:

https://www.linkedin.com/

About BioSpring

BioSpring GmbH is one of the world’s leading contract development and manufacturing organizations (CDMOs) specializing in therapeutic oligonucleotides. Since its founding in 1997, the company has supported biotechnology and pharmaceutical companies worldwide across the entire drug development lifecycle, from early research to commercial manufacturing.

The company has maintained a high-quality manufacturing system for years, having been subject to GMP inspections since 2007 and FDA inspections since 2016.

Currently, to meet the growing global demand for advanced nucleic acid medicines, BioSpring is constructing a new large-scale manufacturing facility in Offenbach, Germany.

For more information, please visit:

https://www.biospring.net/

Contact

Luxana Biotech Co., Ltd. E-mail: info@luxnabiotech.co.jp

Website: https://luxnabiotech.co.jp/